 |
Prospector
Profile
2-22-005
|
| |
| Staar Surgical Company |
NAICS |
339115 |
| 1911 Walker Avenue
Monrovia, CA 91016 |
Description |
Opthalmic Goods Mfg. |
| (626) 303-7902 |
Employees |
284 |
| http://www.staar.com |
Revenue |
(mil) |
0.0600 |
| |
Income |
(mil) |
-0.0200 |
| |
Assets |
(mil) |
47.7700 |
| |
Liability |
(mil) |
16.0100 |
| |
(for the year ended 2006-12-29) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
STAAR Surgical Company reported a net loss of $3.83 million on net sales of $13.63 million for the three months ended September 28, 2007, as compared to a net loss of $2.79 million on net sales of $13.31 million during the three months ended September 29, 2006. For the nine months ended September 28, 2007, the Company reported a net loss of $11.71 million on net sales of $43.48 million compared to the net loss of $9.37 million on net sales of $41.51 million reported during the same period last year. As a result of its recurring losses, the Company has an accumulated deficit of $98.41 million as of September 28, 2007.
|
| |
|
Intellectual Property:
The Company owns or has rights to a number of patents, licenses, trademarks, copyrights, trade secrets and other intellectual property directly related and important to its business. As of December 29, 2006, the Company owned approximately 104 United States and foreign patents and had approximately 42 patent applications pending. The Company believes that patents are important to its business. Of significant importance to the Company are the patents, licenses, and technology rights surrounding its Visian ICL and Collamer material. In 1996, the Company was granted an exclusive royalty-bearing license to manufacture, use, and sell implantable Collamer lenses (ICL) in the United States, Europe, Latin America, Africa, and Asia using the uniquely biocompatible Collamer material. The Collamer material is also used in certain of its IOLs. The Company has also acquired or applied for various patents and licenses related to Aqua Flow Device, phacoemulsification system, insertion devices, and other technologies. [SEC Filing 10-K/A 02-07-08]
|
| |
|
Description:
STAAR Surgical Company engages in the development, production, and marketing of intraocular lenses and other ophthalmic products for minimally invasive ophthalmic surgery.
|
| |
|
Officers:
Don M. Bailey (Chair); Barry G. Caldwell (Pres., CEO & Dir.); Deborah Andrews (VP & CFO)
|
| |
|
Auditor:
BDO Seidman LLP
|
| |
|
Securities:
Common Stock Symbol STAA; NasdaqGM; 29,381,009 common shares outstanding as of November 7, 2007.
|
| |
| |
| |
| return to main page |
|
|
